ALNY News and Press, Alnylam Pharmaceuticals Inc. From 11/02/23

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Alnylam Pharmaceuticals Inc. (ALNY) is expected to report $-1.61 for Q3 2023

2023-11-01 13:10:04 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Set...

– Annual Survey has Ranked Alnylam within the Top Three on the Best Employers List Since 2019 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its third place ranking in Science magazine’s Top Employer Survey f...

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosi...

– Single Doses of ALN-APP Achieve Sustained Pharmacodynamic Activity up to 10 Months After Administration – – Observed Marked Reductions in Aβ 42 and Aβ 40 , Amyloid Fragments Implicated in Alzheimer’s Disease and Cerebral Amyloid Angiopat...

2023-10-22 08:20:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy held up b...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial markets open. Management will provide an update...

2023-10-18 12:49:03 ET Summary Incyte's stock has declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Despite the decline, Incyte reported strong financial performance with a 25% increase in net product revenu...

2023-10-16 18:39:22 ET Summary Arbutus Biopharma Corporation is a small biopharma company focused on developing therapeutics for chronic Hepatitis B virus infection. The company recently dropped two drug candidates in development to increase focus on advancing its primary asset wi...